Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission

REFERENCES

• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051–1062.
   Google Scholar
• Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989;7:1071–1080.
   Google Scholar
• Davis CL, Rohatiner AZ, Lim J, Whelan JS, Oza AM, Amess J, Love S, Stead E, Lister TA. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br J Haematol 1993;83:404–411.
   Google Scholar
• Vignetti M, Orsini E, Petti MC, Moleti ML, Andrizzi C, Pinto RM, Amadori S, Meloni G. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience. Ann Oncol 1996;7:933–938.
   Google Scholar
• Gale RP, Horowitz MM, Rees JK, Gray RG, Oken MM, Estey EH, Kim KM, Zhang MJ, Ash RC, Atkinson K et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 1996;10:13–19.
   Google Scholar
• Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ Rimm AA, Ringden 0, Rozman C, Speck B et al. Graft-versus-leukemia reactions after bone marrow transplan-tation. Blood 1990;75:555–562.
   Google Scholar
• Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E Willman C, Hurd DD, Bennett JM, Blume KG, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649–1656.
   Google Scholar
• Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L Leoni F, Damasio E, Visani G, Papa G et al. Autologous or allogeneic bone marrow transplantation com-pared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332:217–223.
   Google Scholar
• Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998;351:700–708.
   Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leu-kaemia Working Parties. Blood 1998;92:2322–2333.
   Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, et al. Karyotypic analysis predicts outcome of preremis-sion and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075–4083.
   Google Scholar
• Ball ED, Wilson J, Phelps V, Neudorf S. Autologous bone marrow transplantation for acute myeloid leukemia in remis-sion or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up. Bone Marrow Transplant 2000;25:823–829.
   Google Scholar
• Meloni G, Vignetti M, Avvisati G, Capria S, Micozzi A, Giona F, Mandelli F. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplant 1996;18:693–698.
   Google Scholar
• Reece DE, Barnett MJ, Connors JM, Klingemann HG, O'Reilly SE, Shepherd JD, Sutherland HJ, Phillips GL. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxy-cyclophosphamide. Bone Marrow Transplant 1993;11: 139–146.
   Google Scholar
• Klingemann HG, Eaves CJ, Barnett MJ, Eaves AC, Hogge DE, Nantel SH, Reece E, Shepherd JD, Sutherland HJ, Philips GL. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 adminis-tration. Bone Marrow Transplant 1994;14:389–396.
   Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incom-plete observations. J Am Stat Assoc 1958;53:157–181.
   Google Scholar
• Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, Vekhoff A, Sadoun A, Stamatoullas A, Fegueux N et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia. Leukemia 2000;14:1006–1013.
   Google Scholar
• Meloni G, Diverio D, Vignetti M, Avvisati G, Capria S, Petti MC, Lo CF. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997;90:1321–1325.
   Google Scholar
• Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ, Nitta J, Shepherd JD, Sutherland HJ, Toze CL, et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 2002;8:435–443.
   Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der LH, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of che-motherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540 — 1545.
   Google Scholar
• Anal M, Harousseau JL, Stoppa AM, Sotto jj, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
   Google Scholar